ASCO 2021 | P10015/SARC033: trametinib in advanced EHE

Robin Jones, MBBS, MRCP, MD, Royal Marsden NHS Foundation Trust, London, UK, discusses the results from the P10015/SARC033 trial: a Phase II single-arm prospective trial of trametinib in advanced epithelioid hemangioendothelioma (EHE) (NCT03148275); this was the largest prospective trial of this cancer subtype with (n=42). No unexpected safety signals were found, the overall response rate (ORR) was 7%, the median progression free survival (mPFS) was 8.2 months, patients exhibited tumor shrinkage, and the pain outcome measures of patients was improved. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.